Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice

Journal of Human Hypertension volume 20, pages 917–922 (2006)Cite this article

Abstract

Variation in antihypertensive drug utilization and guideline preferences between six European countries (Denmark, Finland, Germany, Norway, Sweden, the Netherlands) was investigated. Our objectives were to compare between-country variability in utilization per class of antihypertensive agents and to assess guideline preferences in relation to actual use. Antihypertensive consumption data (2003) was retrieved. We classified antihypertensive agents using ATC-codes: C02CA – alpha-blockers (AB), C03A – thiazide diuretics (TD), C07AB – beta-blockers (BB), C08CA – dihydropyridine calcium antagonists (CA), C09A/C09BA/C09BB – ACE-inhibitors+combinations (AI) and C09C/C09D – angiotensin II receptor blockers+combinations (AT2). For each class, DDDs/1000 persons/day and share (%) of total antihypertensive utilization was calculated. Per class, relative standard deviations (RSD) across countries were computed. Current hypertension guidelines were requested from national medical associations. Total antihypertensive utilization varied considerably, ranging from 152.4 (Netherlands) to 246.9 (Germany) DDDs/1000 persons/day. RSD was highest for TD (106.2%) and AB (93.6%). Where guidelines advocated TDs (Norway and Netherlands), TD utilization was below (Norway) or just above (Netherlands) median TD use. Guidelines recommended TD (Norway and Netherlands), TD/BB/AI (Finland, German Physicians Association) or TD/BB/CA/AI/AT2 (Denmark, German Hypertension Society), Sweden had no recent national guideline. In conclusion, antihypertensive utilization patterns varied largely across these six countries, in absolute and relative terms. Furthermore, guidelines seem disconnected from clinical practice in some countries, and none of the guidelines discuss current utilization. Whether this reflects a need for change in prescribing or re-evaluation of guidelines warrants further research.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. World Health Organization. The atlas of heart disease and stroke 2004. http://www.who.int/cardiovascular_diseases/resources/atlas/en/(accessed 16 March 2006).

  2. Moser M . World Health Organization – International Society of Hypertension guidelines for the management of hypertension – do these differ from the US recommendations? Which guidelines should the practicing physician follow? J Clin Hypertens 1999; 1: 48–54.

    Google Scholar 

  3. Psaty B, Siscovick D, Weiss N, Koepsell T, Rosendaal F, Lin D et al. Hypertension and outcomes research: from clinical trials to clinical epidemiology. Am J Hypertens 1996; 9: 178–183.

    Article  CAS  PubMed  Google Scholar 

  4. Baksaas I, Fugelli P, Halvorsen IK, Lunde PKM, Naess K . Prescription of hypotensives in general practice. Eur J Clin Pharmacol 1978; 14: 309–317.

    Article  CAS  PubMed  Google Scholar 

  5. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369.

    Article  Google Scholar 

  6. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasma K . Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980 s to mid-1990 s, and the role of medication. BMJ 2006; 332: 629–635.

    Article  PubMed  PubMed Central  Google Scholar 

  7. World Health Organization Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system. http://www.whocc.no/atcddd(accessed 22 March 2006).

  8. United Nations Economic Commission for Europe. UNECE Statistics. http://www.unece.org/stats/stats_h.htm(accessed 22 March 2006).

  9. Organisation for Economic Cooperation and Development. Health at a glance – OECD Indicators 2005. OECD Publishing: Paris (France), 2005.

  10. Begaud B, Bergman U, Eichler HG, Leufkens HG, Meier PJ . Drug reimbursement: indicators of inappropriate resource allocation. Br J Clin Pharmacol 2002; 54: 528–534.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Walma EP, Thomas S, Prins A, Grundmeyer HGLM, van der Laan JR, Wiersma TJ . NHG guideline hypertension, third revision (in Dutch). Huisarts Wet 2003; 46: 435–449.

    Google Scholar 

  12. Meland E, Ellekjær H, Gjelsvik B, Kimsås A, Holmen J, Hetlevik I . Pharmacological prevention of cardiovascular diseases in general practice (in Norwegian). Tidsskr Nor Lægeforen 2000; 120: 2643–2647.

    CAS  PubMed  Google Scholar 

  13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  Google Scholar 

  14. Abildgaard Jacobsen I, Bang LE, Borrild NJ, Feldt-Rasmussen BF, Hansen HS, Ibsen H et al. (eds). Arterial hypertension (in Danish). Danish Hypertension Society 1999. http://www.hypertension.suite.dk/klar999.pdf(accessed 22 March 2006).

  15. Finnish Hypertension Association's Task Force. Treatment of hypertension (in Finnish). Duodecim 2002; 118: 110–126.

  16. Lasek R, Müller-Oerlinghausen B, Berthold HK, Tiaden JD (eds). Recommendations for the therapy of arterial hypertension – second edition (in German). Drug Commission of the German Medical Association 2004. http://www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdf(accessed 22 March 2006).

  17. Guidelines subcommittee. 1999 World Health Organization – International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.

  18. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  19. Bang LE, Bruun NE, Christensen K, Svendsen TL (eds). Arterial hypertension, treatment guideline (in Danish). Danish Hypertension Society – Danish Heart Association 2004. http://www.hypertension.suite.dk/kalender/arkiv/2004/2004(accessed 22 March 2006).

  20. German Hypertension Society. Guideline for the prevention, recognition, diagnosis and therapy of arterial hypertension (in German). German Hypertension Society. 2003. http://www.uni-duesseldorf.de/AWMF/ll/046-001.htm(accessed 22 March 2006).

  21. Anell A, Svarvar P . Pharmacoeconomics and clinical practice guidelines: a survey of attitudes in Swedish formulary committees. Pharmacoeconomics 2000; 17: 175–185.

    Article  CAS  PubMed  Google Scholar 

  22. Swedish Council on Technology Assessment in Health Care. Moderately elevated blood pressure – a systematic literature review (in Swedish – appendix in English). SBU; 2004. Report No.:170/1. http://www.sbu.se/www/subpage.asp?CatID=74&PageID=744(accessed 22 March 2006).

  23. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–2544.

    Article  CAS  Google Scholar 

  24. Fretheim A, Oxman AD . International variation in prescribing antihypertensive drugs: Its extent and possible explanations. BMC Health Serv Res 2005; 5: 21.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Klungel OH, de Boer A, Paes AH, Seidell JC, Nagelkerke NJ, Bakker A . Undertreatment of hypertension in a population-based study in The Netherlands. J Hypertens 1998; 16: 1371–1378.

    Article  CAS  PubMed  Google Scholar 

  26. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001.

  27. Sturm HB, Van Gilst WH, Swedberg K, Hobbs FDR, Haaijer-Ruskamp FM . Heart failure guidelines and prescribing in primary care across Europe. BMC Health Serv Res 2005; 5: 57.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Poluzzi E, Strahinja P, Vargiu A, Chiabrando G, Chiara Silvani M, Motola D et al. Initial treatment of hypertension and adherence tot therapy in general practice in Italy. Eur J Clin Pharmacol 2005; 61: 603–609.

    Article  CAS  PubMed  Google Scholar 

  29. Mantel-Teeuwisse AK, Klungel OH, Hofman A, Verschuren WM, Trienekens PH, Porsius AJ et al. Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992–1999). Br J Clin Pharmacol 2006; 61: 592–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gu Q, Paulose-Ram R, Dillon C, Burt V . Antihypertensive medication use among US adults with hypertension. Circulation 2006; 113: 213–221.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands

    P Stolk, B L G Van Wijk, H G M Leufkens & E R Heerdink

Authors
  1. P Stolk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B L G Van Wijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H G M Leufkens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E R Heerdink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to P Stolk or E R Heerdink.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stolk, P., Van Wijk, B., Leufkens, H. et al. Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice. J Hum Hypertens 20, 917–922 (2006). https://doi.org/10.1038/sj.jhh.1002089

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002089

Keywords

This article is cited by

Search

Advanced search

Quick links